Close
4

Quotient Sciences Quotient Sciences

X

Company profile for KaliVir Immunotherapeutics

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from The University of Pittsburgh’s world-class onco...
KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from The University of Pittsburgh’s world-class oncolytic virus and immunotherapy research program.KaliVir is engineering vaccinia virus-based oncolytic viral immunotherapies that can be delivered intravenously to cancer patients.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
KaliVir Immunotherapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
240 Alpha Drive Pittsburgh, PA 15238
Telephone
Telephone
1.412.435.6730
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY